PULSE BIOSCIENCES, INC. Cash Flow Statement
PLSE / Health Care|12 years of annual SEC 10-K data (FY2014-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 12 fiscal years. All figures from audited SEC 10-K filings.
PULSE BIOSCIENCES, INC. used $54M in operating cash flow and negative free cash flow of $54M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.66 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$72.8M | -$53.6M | -$58.5M | -$58.5M | -$63.7M | -$49.9M | -$47.0M | -$37.5M | -$25.6M | -$9.5M | -$2.8M | -$277.0K |
| Depreciation & Amortization | - | - | $690.0K | - | - | $430.0K | $494.0K | $645.0K | $336.0K | $94.0K | $51.0K | $6.0K |
| Operating Cash Flow | -$54.1M | -$36.3M | -$47.0M | -$47.0M | -$54.1M | -$35.4M | -$34.2M | -$23.9M | -$11.1M | -$8.1M | -$3.3M | -$101.0K |
| Capital Expenditures | $315.0K | $125.0K | $401.0K | $401.0K | $437.0K | $441.0K | $608.0K | $276.0K | $2.6M | $64.0K | $86.0K | $46.0K |
| Free Cash Flow | -$54.4M | -$36.5M | -$47.4M | -$47.4M | -$54.5M | -$35.8M | -$34.8M | -$24.2M | -$13.6M | -$8.1M | -$3.4M | -$147.0K |
| FCF Margin | -15553.4% | - | -6773.4% | -6773.4% | -3845.8% | - | - | - | - | - | - | - |